

Rosa María Hernández

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4285702/publications.pdf>

Version: 2024-02-01

195
papers

10,864
citations

36303

51
h-index

37204

96
g-index

196
all docs

196
docs citations

196
times ranked

13161
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Hair Follicle-Derived Mesenchymal Stromal Cells from the Lower Dermal Sheath as a Competitive Alternative for Immunomodulation. <i>Biomedicines</i> , 2022, 10, 253.	3.2	7
2	Bioactive and degradable hydrogel based on human platelet-rich plasma fibrin matrix combined with oxidized alginate in a diabetic mice wound healing model. <i>Materials Science and Engineering C</i> , 2022, 135, 112695.	7.3	15
3	Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 31-40.	4.3	5
4	Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 22.	5.0	5
5	Cell-based dressings: A journey through chronic wound management. , 2022, 135, 212738.		10
6	Extracellular vesicles from hair follicle-derived mesenchymal stromal cells: isolation, characterization and therapeutic potential for chronic wound healing. <i>Stem Cell Research and Therapy</i> , 2022, 13, 147.	5.5	20
7	Green hemostatic sponge-like scaffold composed of soy protein and chitin for the treatment of epistaxis. <i>Materials Today Bio</i> , 2022, 15, 100273.	5.5	5
8	Clinical progress in MSC-based therapies for the management of severe COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 25-36.	7.2	10
9	Cell microencapsulation technologies for sustained drug delivery: Clinical trials and companies. <i>Drug Discovery Today</i> , 2021, 26, 852-861.	6.4	11
10	Characterization of Bio-Inspired Electro-Conductive Soy Protein Films. <i>Polymers</i> , 2021, 13, 416.	4.5	9
11	Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases. <i>Drug Delivery and Translational Research</i> , 2021, 11, 498-514.	5.8	5
12	GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. <i>FASEB Journal</i> , 2021, 35, e21422.	0.5	9
13	3D Bioprinting of Functional Skin Substitutes: From Current Achievements to Future Goals. <i>Pharmaceutics</i> , 2021, 14, 362.	3.8	32
14	Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety. <i>Journal of Controlled Release</i> , 2021, 335, 619-636.	9.9	31
15	Immunomodulatory Biomaterials for Tissue Repair. <i>Chemical Reviews</i> , 2021, 121, 11305-11335.	47.7	121
16	Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues. <i>Pharmaceutics</i> , 2021, 13, 1802.	4.5	30
17	Mesenchymal stromal cell based therapies for the treatment of immune disorders: recent milestones and future challenges. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 189-200.	5.0	21
18	Surface indicators are correlated with soil multifunctionality in global drylands. <i>Journal of Applied Ecology</i> , 2020, 57, 424-435.	4.0	35

#	ARTICLE	IF	CITATIONS
19	Nanostructured Lipid Carriers Made of ω -3 Polyunsaturated Fatty Acids: In Vitro Evaluation of Emerging Nanocarriers to Treat Neurodegenerative Diseases. <i>Pharmaceutics</i> , 2020, 12, 928.	4.5	8
20	Multifunctional biomimetic hydrogel systems to boost the immunomodulatory potential of mesenchymal stromal cells. <i>Biomaterials</i> , 2020, 257, 120266.	11.4	44
21	3D encapsulation and inflammatory licensing of mesenchymal stromal cells alter the expression of common reference genes used in real-time RT-qPCR. <i>Biomaterials Science</i> , 2020, 8, 6741-6753.	5.4	4
22	Chronic wounds: Current status, available strategies and emerging therapeutic solutions. <i>Journal of Controlled Release</i> , 2020, 328, 532-550.	9.9	151
23	Overcoming the Inflammatory Stage of Non-Healing Wounds: In Vitro Mechanism of Action of Negatively Charged Microspheres (NCMs). <i>Nanomaterials</i> , 2020, 10, 1108.	4.1	14
24	Structure-properties relationship of chitosan/collagen films with potential for biomedical applications. <i>Carbohydrate Polymers</i> , 2020, 237, 116159.	10.2	85
25	In vitro and in vivo antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC). <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102259.	3.3	12
26	Soy protein and chitin sponge-like scaffolds: from natural by-products to cell delivery systems for biomedical applications. <i>Green Chemistry</i> , 2020, 22, 3445-3460.	9.0	23
27	Clinical Applications of Cell Encapsulation Technology. <i>Methods in Molecular Biology</i> , 2020, 2100, 473-491.	0.9	9
28	Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin. <i>Journal of Biophotonics</i> , 2019, 12, e201800170.	2.3	4
29	Extracellular matrix protein microarray-based biosensor with single cell resolution: Integrin profiling and characterization of cell-biomaterial interactions. <i>Sensors and Actuators B: Chemical</i> , 2019, 299, 126954.	7.8	16
30	Development of Bioinspired Gelatin and Gelatin/Chitosan Bilayer Hydrofilms for Wound Healing. <i>Pharmaceutics</i> , 2019, 11, 314.	4.5	44
31	Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118484.	5.2	28
32	GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells. <i>Cell Death and Differentiation</i> , 2019, 26, 1998-2014.	11.2	22
33	Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against <i>P. aeruginosa</i> : in vitro and in vivo studies following pulmonary and intramuscular administration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 101-111.	3.3	22
34	Type 1 Diabetes Mellitus reversal via implantation of magnetically purified microencapsulated pseudoislets. <i>International Journal of Pharmaceutics</i> , 2019, 560, 65-77.	5.2	12
35	Review of Advanced Hydrogel-Based Cell Encapsulation Systems for Insulin Delivery in Type 1 Diabetes Mellitus. <i>Pharmaceutics</i> , 2019, 11, 597.	4.5	56
36	Force spectroscopy-based simultaneous topographical and mechanical characterization to study polymer-to-polymer interactions in coated alginate microspheres. <i>Scientific Reports</i> , 2019, 9, 20112.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Composite nanofibrous membranes of PLGA/Aloe vera containing lipid nanoparticles for wound dressing applications. <i>International Journal of Pharmaceutics</i> , 2019, 556, 320-329.	5.2	55
38	Hyaluronic acid enhances cell survival of encapsulated insulin-producing cells in alginate-based microcapsules. <i>International Journal of Pharmaceutics</i> , 2019, 557, 192-198.	5.2	34
39	Hyaluronic Acid Promotes Differentiation of Mesenchymal Stem Cells from Different Sources toward Pancreatic Progenitors within Three-Dimensional Alginate Matrixes. <i>Molecular Pharmaceutics</i> , 2019, 16, 834-845.	4.6	15
40	3D cell-laden polymers to release bioactive products in the eye. <i>Progress in Retinal and Eye Research</i> , 2019, 68, 67-82.	15.5	15
41	Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and Nrf2 regulation. <i>Neurobiology of Disease</i> , 2019, 121, 252-262.	4.4	67
42	Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes. <i>Trends in Biotechnology</i> , 2018, 36, 445-456.	9.3	62
43	Microencapsulated macrophages releases conditioned medium able to prevent epithelial to mesenchymal transition. <i>Drug Delivery</i> , 2018, 25, 91-101.	5.7	3
44	Characterization of an encapsulated insulin secreting human pancreatic beta cell line in a modular microfluidic device. <i>Journal of Drug Targeting</i> , 2018, 26, 36-44.	4.4	15
45	Alginate Microcapsules for Drug Delivery. <i>Springer Series in Biomaterials Science and Engineering</i> , 2018, , 67-100.	1.0	11
46	The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment. <i>Current Drug Delivery</i> , 2018, 15, 1218-1220.	1.6	3
47	Graphene oxide enhances alginate encapsulated cells viability and functionality while not affecting the foreign body response. <i>Drug Delivery</i> , 2018, 25, 1147-1160.	5.7	25
48	Advances in the slow freezing cryopreservation of microencapsulated cells. <i>Journal of Controlled Release</i> , 2018, 281, 119-138.	9.9	48
49	3D Printed porous polyamide macrocapsule combined with alginate microcapsules for safer cell-based therapies. <i>Scientific Reports</i> , 2018, 8, 8512.	3.3	25
50	Low molecular-weight hyaluronan as a cryoprotectant for the storage of microencapsulated cells. <i>International Journal of Pharmaceutics</i> , 2018, 548, 206-216.	5.2	4
51	Preparation and Characterization of Resveratrol Loaded Pectin/Alginate Blend Gastro-Resistant Microparticles. <i>Molecules</i> , 2018, 23, 1886.	3.8	16
52	Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 145-155.	4.0	95
53	Hybrid Alginate-Protein-Coated Graphene Oxide Microcapsules Enhance the Functionality of Erythropoietin Secreting C ₂ C ₁₂ Myoblasts. <i>Molecular Pharmaceutics</i> , 2017, 14, 885-898.	4.6	13
54	Nanotechnology-based delivery systems to release growth factors and other endogenous molecules for chronic wound healing. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 2-17.	3.0	28

#	ARTICLE	IF	CITATIONS
55	Alginate Microcapsules Incorporating Hyaluronic Acid Recreate Closer <i>in Vivo</i> Environment for Mesenchymal Stem Cells. <i>Molecular Pharmaceutics</i> , 2017, 14, 2390-2399.	4.6	28
56	Cell microencapsulation technology: Current vision of its therapeutic potential through the administration routes. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 49-62.	3.0	30
57	Improved control over MSCs behavior within 3D matrices by using different cell loads in both <i>in vitro</i> and <i>in vivo</i> environments. <i>International Journal of Pharmaceutics</i> , 2017, 533, 62-72.	5.2	4
58	Ultra thin hydro-films based on lactose-crosslinked fish gelatin for wound healing applications. <i>International Journal of Pharmaceutics</i> , 2017, 530, 455-467.	5.2	36
59	The role of osmolarity adjusting agents in the regulation of encapsulated cell behavior to provide a safer and more predictable delivery of therapeutics. <i>Drug Delivery</i> , 2017, 24, 1654-1666.	5.7	13
60	Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. <i>International Journal of Pharmaceutics</i> , 2017, 523, 556-566.	5.2	145
61	Use of Flow Focusing Technique for Microencapsulation of Myoblasts. <i>Methods in Molecular Biology</i> , 2017, 1479, 207-216.	0.9	2
62	Microencapsulated Cells for Cancer Therapy. <i>Methods in Molecular Biology</i> , 2017, 1479, 261-272.	0.9	2
63	Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors. <i>Molecular Neurobiology</i> , 2017, 54, 7722-7735.	4.0	4
64	Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment. , 2017, , 57-87.		3
65	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5
66	Nanotechnology-based drug-delivery systems releasing growth factors to the CNS. , 2016, , 371-402.		3
67	Intranasal Administration of Chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 2220-2280.	1.1	65
68	Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases. <i>Nanomedicine</i> , 2016, 11, 1267-1285.	3.3	35
69	LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 310-316.	4.3	76
70	Nanotechnology approaches for skin wound regeneration using drug-delivery systems. , 2016, , 31-55.		10
71	Nanoparticle transport across <i>in vitro</i> olfactory cell monolayers. <i>International Journal of Pharmaceutics</i> , 2016, 499, 81-89.	5.2	81
72	Optoacoustic imaging enabled biodistribution study of cationic polymeric biodegradable nanoparticles. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 421-427.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Specific requirements regarding module 5. Pharmaceuticals Policy and Law, 2015, 17, 279-281.	0.1	0
74	Development and in vitro evaluation of lipid nanoparticle-based dressings for topical treatment of chronic wounds. International Journal of Pharmaceutics, 2015, 490, 404-411.	5.2	29
75	Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 105-112.	2.8	15
76	Assessment of the Behavior of Mesenchymal Stem Cells Immobilized in Biomimetic Alginate Microcapsules. Molecular Pharmaceutics, 2015, 12, 3953-3962.	4.6	22
77	Advances in cell encapsulation technology and its application in drug delivery. Expert Opinion on Drug Delivery, 2015, 12, 1251-1267.	5.0	31
78	Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin. International Journal of Pharmaceutics, 2015, 485, 15-24.	5.2	32
79	Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 91, 91-102.	4.3	25
80	Graphene oxide increases the viability of C2C12 myoblasts microencapsulated in alginate. International Journal of Pharmaceutics, 2015, 493, 260-270.	5.2	34
81	Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids and Surfaces B: Biointerfaces, 2015, 134, 304-313.	5.0	135
82	Specific requirements for somatic cell therapy medicinal products and tissue engineered products. Pharmaceuticals Policy and Law, 2015, 17, 271-277.	0.1	0
83	Cell encapsulation: technical and clinical advances. Trends in Pharmacological Sciences, 2015, 36, 537-546.	8.7	151
84	Advances in drug delivery systems (DDSs) to release growth factors for wound healing and skin regeneration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1551-1573.	3.3	211
85	Evaluation of different RGD ligand densities in the development of cell-based drug delivery systems. Journal of Drug Targeting, 2015, 23, 806-812.	4.4	14
86	Design and evaluation of surface and adjuvant modified PLGA microspheres for uptake by dendritic cells to improve vaccine responses. International Journal of Pharmaceutics, 2015, 496, 371-381.	5.2	30
87	Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease: Effects of Nanoencapsulated Neurotrophic Factors Administration. Molecular Neurobiology, 2015, 52, 846-858.	4.0	18
88	Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. Journal of Drug Targeting, 2015, 23, 170-179.	4.4	24
89	The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model. Journal of Controlled Release, 2015, 197, 41-47.	9.9	100
90	Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction. Mini-Reviews in Medicinal Chemistry, 2015, 15, 490-502.	2.4	2

#	ARTICLE	IF	CITATIONS
91	Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease. <i>International Journal of Nanomedicine</i> , 2014, 9, 2677.	6.7	42
92	The synergistic effects of the RGD density and the microenvironment on the behavior of encapsulated cells: In vitro and in vivo direct comparative study. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, 3965-3972.	4.0	16
93	Behaviour and ultrastructure of human bone marrow-derived mesenchymal stem cells immobilised in alginate-poly-L-lysine-alginate microcapsules. <i>Journal of Microencapsulation</i> , 2014, 31, 579-589.	2.8	17
94	Application of cell encapsulation for controlled delivery of biological therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2014, 67-68, 3-14.	13.7	100
95	Nanotherapeutic approaches for brain cancer management. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e905-e919.	3.3	87
96	Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PLGA nanoparticles. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 972, 95-101.	2.3	4
97	A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. <i>Journal of Controlled Release</i> , 2014, 185, 51-61.	9.9	143
98	Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response. <i>Acta Biomaterialia</i> , 2014, 10, 4206-4216.	8.3	29
99	Designing improved poly lactic-co-glycolic acid microspheres for a malarial vaccine: incorporation of alginate and polyinosinic-polycytidilic acid. <i>Journal of Microencapsulation</i> , 2014, 31, 560-566.	2.8	6
100	Encapsulation of Cells in Alginate Gels. <i>Methods in Molecular Biology</i> , 2013, 1051, 313-325.	0.9	11
101	VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer's disease. <i>Journal of Controlled Release</i> , 2013, 170, 111-119.	9.9	56
102	Therapeutic Applications of Encapsulated Cells. <i>Methods in Molecular Biology</i> , 2013, 1051, 349-364.	0.9	13
103	Decoupling of soil nutrient cycles as a function of aridity in global drylands. <i>Nature</i> , 2013, 502, 672-676.	27.8	733
104	Hydrogel-Based Scaffolds for Enclosing Encapsulated Therapeutic Cells. <i>Biomacromolecules</i> , 2013, 14, 322-330.	5.4	18
105	rhEGF-loaded PLGA-Alginate microspheres enhance the healing of full-thickness excisional wounds in diabetised Wistar rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 243-252.	4.0	61
106	In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 1183-1190.	4.3	58
107	A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 84, 29-39.	4.3	38
108	Therapeutic cell encapsulation: Ten steps towards clinical translation. <i>Journal of Controlled Release</i> , 2013, 170, 1-14.	9.9	75

#	ARTICLE	IF	CITATIONS
109	Inactivation of encapsulated cells and their therapeutic effects by means of TGL triple-fusion reporter/biosafety gene. <i>Biomaterials</i> , 2013, 34, 1442-1451.	11.4	16
110	Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research. <i>BioMed Research International</i> , 2013, 2013, 1-19.	1.9	35
111	Plant Species Richness and Ecosystem Multifunctionality in Global Drylands. <i>Science</i> , 2012, 335, 214-218.	12.6	1,043
112	Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions. <i>Expert Review of Vaccines</i> , 2012, 11, 1071-1086.	4.4	11
113	Encapsulated VEGF-Secreting Cells Enhance Proliferation of Neuronal Progenitors in the Hippocampus of A β PP/Ps1 Mice. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 187-200.	2.6	30
114	Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. <i>Vaccine</i> , 2012, 30, 589-596.	3.8	37
115	Stem cells in alginate bioscaffolds. <i>Therapeutic Delivery</i> , 2012, 3, 761-774.	2.2	18
116	A Perspective on Bioactive Cell Microencapsulation. <i>BioDrugs</i> , 2012, 26, 283-301.	4.6	31
117	Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. <i>Clinical and Translational Oncology</i> , 2012, 14, 83-93.	2.4	239
118	Novel advances in the design of three-dimensional bio-scaffolds to control cell fate: translation from 2D to 3D. <i>Trends in Biotechnology</i> , 2012, 30, 331-341.	9.3	121
119	Optimization of 100 μ m alginate-poly-L-lysine-alginate capsules for intravitreal administration. <i>Journal of Controlled Release</i> , 2012, 158, 443-450.	9.9	36
120	A Perspective on Bioactive Cell Microencapsulation. <i>BioDrugs</i> , 2012, 26, 283-301.	4.6	2
121	Novel extended-release formulation of lovastatin by one-step melt granulation: In vitro and in vivo evaluation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 306-312.	4.3	24
122	Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 32-40.	4.0	48
123	Encapsulation of A β 1-15 in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 200-206.	4.0	16
124	Emerging technologies in the delivery of erythropoietin for therapeutics. <i>Medicinal Research Reviews</i> , 2011, 31, 284-309.	10.5	20
125	Design of a composite drug delivery system to prolong functionality of cell-based scaffolds. <i>International Journal of Pharmaceutics</i> , 2011, 407, 142-150.	5.2	32
126	An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines. <i>Journal of Drug Delivery</i> , 2011, 2011, 1-18.	2.5	54

#	ARTICLE	IF	CITATIONS
127	Microcapsules and microcarriers for in situ cell delivery. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 711-730.	13.7	323
128	Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1621-1631.	4.2	38
129	Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. <i>Journal of Controlled Release</i> , 2010, 146, 93-98.	9.9	29
130	The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer's disease. <i>Biomaterials</i> , 2010, 31, 5608-5618.	11.4	114
131	Biomaterials in Cell Microencapsulation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 5-21.	1.6	73
132	Recent advances in the use of encapsulated cells for effective delivery of therapeutics. <i>Therapeutic Delivery</i> , 2010, 1, 387-396.	2.2	7
133	Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. <i>Drug Delivery</i> , 2010, 17, 490-499.	5.7	16
134	In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: Level A in vitro-in vivo correlation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 75, 232-237.	4.3	17
135	Epo Delivery by Genetically Engineered C2C12 Myoblasts Immobilized in Microcapsules. <i>Advances in Experimental Medicine and Biology</i> , 2010, 670, 54-67.	1.6	3
136	Bioactive cell-hydrogel microcapsules for cell-based drug delivery. <i>Journal of Controlled Release</i> , 2009, 135, 203-210.	9.9	94
137	Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. <i>Journal of Controlled Release</i> , 2009, 137, 174-178.	9.9	49
138	Biocompatibility and in vivo evaluation of oligochitosans as cationic modifiers of alginate/Ca microcapsules. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 91A, 1119-1130.	4.0	18
139	Cryopreservation based on freezing protocols for the long-term storage of microencapsulated myoblasts. <i>Biomaterials</i> , 2009, 30, 3495-3501.	11.4	46
140	Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1504-1517.	2.4	3
141	Cell microencapsulation technology: Towards clinical application. <i>Journal of Controlled Release</i> , 2008, 132, 76-83.	9.9	314
142	β -Irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPF66 synthetic vaccine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 519-526.	4.3	41
143	Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to <i>Plasmodium falciparum</i> MSP2 long synthetic peptides in mice. <i>Vaccine</i> , 2007, 25, 877-885.	3.8	36
144	In Vitro Characterization and In Vivo Functionality of Erythropoietin-Secreting Cells Immobilized in Alginate-Poly-L-Lysine-Alginate Microcapsules. <i>Biomacromolecules</i> , 2007, 8, 3302-3307.	5.4	59

#	ARTICLE	IF	CITATIONS
145	Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. <i>International Journal of Pharmaceutics</i> , 2007, 343, 69-78.	5.2	64
146	Encapsulation of Cells in Alginate Gels. <i>Methods in Biotechnology</i> , 2006, , 345-355.	0.2	22
147	Chemistry and the biological response against immunoisolating alginate- ϵ -polycation capsules of different composition. <i>Biomaterials</i> , 2006, 27, 4831-4839.	11.4	99
148	Evaluation of human serum albumin as a substitute of foetal bovine serum for cell culture. <i>International Journal of Pharmaceutics</i> , 2006, 310, 8-14.	5.2	16
149	In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. <i>Journal of Controlled Release</i> , 2006, 116, 28-34.	9.9	47
150	Biomedical Applications of Immobilized Cells. <i>Methods in Biotechnology</i> , 2006, , 427-437.	0.2	3
151	Microcapsules prepared with different biomaterials to immobilize GDNF secreting 3T3 fibroblasts. <i>International Journal of Pharmaceutics</i> , 2005, 293, 1-10.	5.2	20
152	Biocompatible oligochitosans as cationic modifiers of alginate/Ca microcapsules. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2005, 74B, 429-439.	3.4	23
153	Long-Term Expression of Erythropoietin from Myoblasts Immobilized in Biocompatible and Neovascularized Microcapsules. <i>Molecular Therapy</i> , 2005, 12, 283-289.	8.2	70
154	The influence of cellular seeding density in the microencapsulation of hybridoma cells. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2005, 16, 521-529.	3.5	5
155	Biocompatibility Evaluation of Different Alginates and Alginate-Based Microcapsules. <i>Biomacromolecules</i> , 2005, 6, 927-931.	5.4	109
156	Comparative study of microcapsules elaborated with three polycations (PLL, PDL, PLO) for cell immobilization. <i>Journal of Microencapsulation</i> , 2005, 22, 303-315.	2.8	56
157	Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 132-40.	2.1	18
158	History, challenges and perspectives of cell microencapsulation. <i>Trends in Biotechnology</i> , 2004, 22, 87-92.	9.3	333
159	The search for new β -cell sources. <i>Trends in Biotechnology</i> , 2004, 22, 612-613.	9.3	2
160	Enhancing Immunogenicity and Reducing Dose of Microparticulated Synthetic Vaccines: Single Intradermal Administration. <i>Pharmaceutical Research</i> , 2004, 21, 121-126.	3.5	28
161	Techniques: New approaches to the delivery of biopharmaceuticals. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 382-387.	8.7	87
162	Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. <i>Vaccine</i> , 2004, 22, 1423-1432.	3.8	83

#	ARTICLE	IF	CITATIONS
163	Survival of different cell lines in alginate-agarose microcapsules. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 18, 23-30.	4.0	95
164	Controversies over stem cell research. <i>Trends in Biotechnology</i> , 2003, 21, 109-112.	9.3	15
165	Drug delivery in biotechnology: present and future. <i>Current Opinion in Biotechnology</i> , 2003, 14, 659-664.	6.6	198
166	Development and optimisation of alginate-PMCG-alginate microcapsules for cell immobilisation. <i>International Journal of Pharmaceutics</i> , 2003, 259, 57-68.	5.2	67
167	Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. <i>International Journal of Pharmaceutics</i> , 2003, 260, 273-282.	5.2	43
168	Cell encapsulation: Promise and progress. <i>Nature Medicine</i> , 2003, 9, 104-107.	30.7	546
169	Cell microencapsulation technology for biomedical purposes: novel insights and challenges. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 207-210.	8.7	127
170	Immune responses to orally administered PLGA microparticles: influence of oil vehicles and surfactive agents. <i>Journal of Microencapsulation</i> , 2003, 20, 525-536.	2.8	3
171	Preparation and stability of agarose microcapsules containing BCG. <i>Journal of Microencapsulation</i> , 2002, 19, 237-244.	2.8	14
172	Remarkably high antibody levels and protection against <i>P. falciparum</i> malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. <i>Vaccine</i> , 2002, 20, 1707-1710.	3.8	50
173	Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. <i>Vaccine</i> , 2002, 20, 2181-2190.	3.8	41
174	Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. <i>Vaccine</i> , 2002, 21, 67-77.	3.8	255
175	Encapsulated cell technology: from research to market. <i>Trends in Biotechnology</i> , 2002, 20, 382-387.	9.3	59
176	Release of salbutamol sulphate and ketoprofen enantiomers from matrices containing HPMC and cellulose derivatives. <i>Chirality</i> , 2002, 14, 806-813.	2.6	13
177	Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 293-300.	1.9	1
178	Release of ketoprofen enantiomers from HPMC K100M matrices—diffusion studies. <i>International Journal of Pharmaceutics</i> , 2002, 239, 61-68.	5.2	24
179	Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. <i>Biomaterials</i> , 2002, 23, 3825-3831.	11.4	256
180	Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. <i>Vaccine</i> , 2001, 19, 4445-4451.	3.8	55

#	ARTICLE	IF	CITATIONS
181	Preliminary Assessment of the Immune Response to <i>Olea europaea</i> Pollen Extracts Encapsulated into PLGA Microspheres. <i>Pharmaceutical Development and Technology</i> , 2001, 6, 621-627.	2.4	13
182	Microencapsulation of an anti-VEGF cadherin antibody secreting 1B5 hybridoma cells. <i>Biotechnology and Bioengineering</i> , 2001, 76, 285-294.	3.3	38
183	Effect of aging on the release of salbutamol sulfate from lipid matrices. <i>International Journal of Pharmaceutics</i> , 2000, 208, 13-21.	5.2	23
184	Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. <i>Journal of Controlled Release</i> , 1998, 56, 63-73.	9.9	93
185	Release of salbutamol sulfate enantiomers from hydroxypropylmethylcellulose matrices. <i>International Journal of Pharmaceutics</i> , 1998, 161, 37-43.	5.2	20
186	Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. <i>International Journal of Pharmaceutics</i> , 1998, 169, 45-54.	5.2	54
187	Pharmacokinetics and Tissue Distribution of Intravenous Ofloxacin for Antibiotic Prophylaxis in Biliary Surgery. <i>Clinical Drug Investigation</i> , 1998, 15, 491-496.	2.2	6
188	Determination of salbutamol enantiomers by high-performance capillary electrophoresis and its application to dissolution assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 357-366.	2.8	27
189	Correlation of <i>in vitro</i> release and <i>in vivo</i> absorption characteristics of four salbutamol sulphate formulations. <i>International Journal of Pharmaceutics</i> , 1996, 139, 45-52.	5.2	8
190	Influence of Partial Hepatectomy on Theophylline Pharmacokinetics in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 1133-1135.	3.3	5
191	The Influence of Adrenalin on the Pharmacokinetics of Interpleurally Administered Lidocaine in Patients With Pancreatic Neoplasia. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 426-431.	2.0	5
192	Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. <i>Pharmaceutical Research</i> , 1994, 11, 945-950.	3.5	27
193	Platelet Adhesivity to Subendothelium Is Influenced by Polymorphonuclear Leukocytes: Studies with Aspirin and Salicylate. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1993, 23, 1-7.	0.3	3
194	Rheological behaviour of hydrophilic polymers and drug release from erodible matrices. <i>Journal of Controlled Release</i> , 1992, 18, 205-212.	9.9	47
195	PHARMACOKINETICS AND DISTRIBUTION OF KETAMINE AFTER EXTRADURAL ADMINISTRATION TO DOGS. <i>British Journal of Anaesthesia</i> , 1991, 67, 310-316.	3.4	46